At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 282 enrolled
Drug / intervention
Varenicline +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation
In Brief
A Phase 3 clinical trial evaluating Varenicline, Bupropion, and 4 other interventions for Nicotine Dependence. Completed, enrolled 282 participants across 2 sites.
Detailed Summary
The purpose of this study is to look at brain function in order to understand how different treatments work to help people quit smoking. In this study, the investigators will look at the effects of nicotine patches, Chantix alone or Chantix paired with Zyban.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedAug 2011
Primary CompletionDec 2013
Study CompletionJun 2014
TodayJul 2026
First PostedAug 1, 2011
Enrollment StartJul 1, 2011
Primary CompletionDec 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 14.9 years ago
Interventions
Vareniclinedrug
Bupropiondrug
Nicotine patchesdrug
Placebo vareniclineother
Placebo bupropionother
Placebo patchother